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Background: An ability to predict the response to conventional non-surgical 
treatment of a periodontal site would be advantageous. However, so far the 
biomarkers or tests devised to achieve this have lacked sensitivity. The aim of this 
study was to assess the ability of a novel combination of biomarkers to predict the 
outcome of treatment of patients with chronic periodontitis. 
Methods: GCF and subgingival plaque were collected from 77 patients at 3 
UHSUHVHQWDWLYHVLWHVKHDOWK\PPDQGGLVHDVHGPPDWEDVHOLQHDQGDW
and 6-months post treatment. Patients received standard nonsurgical periodontal 
treatment at each time point as appropriate. The outcome measure was 
improvement in pockeWGHSWKRIPP Concentrations of active enzymes (MMP 8, 
elastase and sialidase) in GCF and subgingival plaque levels of Porphyromonas 
gingivalis, Tannerella forsythia and Fusobacterium nucleatum were analysed for 
prediction of the outcome measure. 
Results: 8VLQJ WKUHVKROG YDOXHV RI 003 QJȝO HODVWDVH QJȝO VLDOLGDVH
QJȝO P. gingivalis (0.23%) and T. forsythia (0.35%), Receiver Operating 
Characteristic curves analysis demonstrated that these biomarkers at baseline 
could differentiate KHDOWK\ IURP GLVHDVHG VLWHV VHQVLWLYLW\ DQG VSHFLILFLW\ 
Furthermore, logistic regression showed that this combination of the above 
biomarkers at baseline SURYLGHGDFFXUDWHSUHGLFWLRQVRIWUHDWPHQWRXWFRPH 
Conclusion: 7KHµILQJHUSULQW¶Rf GCF enzymes and bacteria described here offers 
a way to predict the outcome of non-surgical periodontal treatment on a site-specific 
basis.  
Key words: Periodontitis; Gingival crevicular fluid; Prognosis;;; Microbiology  
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Introduction 
 
While diagnosis of periodontal disease per se is well established and employs easy 
to use and relatively non-invasive procedures, there are a number of limitations. 
Specifically, an ability to predict the response to treatment or the likelihood of future 
tissue breakdown is absent1,2,3. Thus, there is a need for alternative diagnostic 
approaches that could be applied at initial triage and be used to direct treatment 
planning regimens. One approach is the use of biomarkers3,4. 
 
Various molecular biomarkers for periodontitis have been examined5-7, particularly 
in saliva, plaque and gingival crevicular fluid (GCF). Although, a focus has been on 
GCF constituents8,9, most of the tests devised so far have lacked sensitivity. This is 
likely to be due to the complex nature of periodontitis such that a single parameter 
is unlikely to be sufficiently discriminating10,11. Our team previously identified as part 
of a pilot study that a combination of high levels of three GCF enzymes, prior to 
treatment provided a predictive value of the outcome of conventional non-surgical 
treatment of 88%, compared to 61% for each enzyme alone12. The biomarkers were 
easily assayed and were representative of inflammation (MMP-8, elastase) and 
physiologically relevant bacterial community activity (sialidase).  
 
As well as GCF biochemical biomarkers, presence and levels of key bacteria have 
been used as possible biomarkers of disease. Most attention has been directed at 
P. gingivalis and T. forsythia, members of the so-FDOOHG µUHG FRPSOH[¶ RI
periodontopathogens13,14, since these bacteria are generally found at higher levels 
in association with disease. In this longitudinal clinical study we have extended our 
earlier findings using MMP8, elastase and sialidase to a larger cohort of patients 
and determined whether addition of key bacteria to these GCF enzyme activities 
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could provide a profile with enhanced predictive value for the outcome of non-
surgical periodontal treatment. 
 
Materials and methods 
Patient population 
The prospective study was approved by the NRES Committee Yorkshire and 
Humberside, (study number: 13/YH/0114, 16th May 2013). Patients attended the 
Periodontology Clinic in the Charles Clifford Dental Hospital, Sheffield, UK between 
2013 and 2015. Potential participants were screened by the consultant periodontist 
(AR) against the inclusion criteria of DJH  \HDUV possession of  WHHWK
diagnosis of chronic periodontitis with several diseased sites. Three individual sites 
were chosen at random for study LQFOXGLQJ RQH GHHS EOHHGLQJ '% PP RQH
deep non-EOHHGLQJ1%PPDQGRQHKHDOWK\PPVLWHFor the diseased sites 
these were the deepest and most accessible sites available. Patient exclusion 
criteria were receipt of antibiotics or periodontal treatment in the 3 months 
preceding the study, pregnancy and lactation, a history of systemic disease or 
medication that may affect the periodontal condition. The subjects did not use 
chlorhexidine. Written consent was obtained from individuals entering the study. 
 
Clinical measures and periodontal treatment 
Full mouth clinical parameters of probing pocket depth (PPD), plaque index (PI)15, 
bleeding on probing (BOP) and clinical attachment level (CAL) were recorded at six 
sites per tooth. The presence or absence of plaque was identified using a Langer 
curette and the parameters of PPD, CAL and BOP (within 30sec) were obtained 
using a UNC15 probe. Two dental therapists, who had been internally calibrated,  
provided standardised non-surgical treatment to manage their periodontal condition 
and also collected full mouth clinical data.  These workers were blind to the clinical 
measurements recorded in the data capture forms of previous visits to avoid bias.  
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Clinical data and samples were collected at baseline, 3 and 6 months.  
Management included oral hygiene instruction, scaling and root surface 
GHEULGHPHQWXQGHUORFDODQDHVWKHVLDIRUVLWHVPPLQGHSWK. A reduction of 2mm 
or more in PPD from the baseline was taken to indicate that the site had responded 
to treatment. Sites  PP were reviewed and retreated 3 months and 6 months 
later as appropriate.  
 
GCF and plaque sample collection and analysis 
The sites selected for sampling were isolated and dried with cotton wool, and 
protected from salivary and blood contamination. Supragingival plaque was 
removed, the tooth air-dried and GCF collected using paper strips* placed in the 
entrance of the periodontal crevice or pockets for 30 sec4,16.  
 
The GCF volumes were immediately determined as described by Griffiths17 or by 
weighing when their volume was outside the accurate range of the machine (i.e. 
above 1.7 ol). To recover the enzymes from the samples, the paper strips were 
eluted for 1 hour in 105µl of sterile phosphate buffered saline (PBS, pH 7.3) 
containing 1% bovine serum albumin. The samples were then centrifuged at 
10,000g for 15 minutes by centrifugal filtrationÁ. The GCF samples were analysed 
immediately for the concentration of active MMP8, elastase and sialidase as 
described by Gul9. Subgingival plaque samples were collected with a sterile curette 
from the same three representative sites at each time point, placed in 500 ol sterile 
PBS and stored at -80¡C until DNA was extracted and analysed by 16srRNA qPCR 
for the levels of P. gingivalis, T. forsythia and F. nucleatum. (Supplementary 
methods). The enzyme and bacterial parameters in all samples were analysed by a 
single independent investigator.  Similar methodology has been used by others18. 
                                                     
*
 Periopaper¨ strips, Oraflow Inc., Plainview, NY, USA 

 Periotron 8000, Oraflow Inc., Plainview, NY, USA 
Á
 Millipore Ltd, UK 
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Statistical methods  
All statistical methods employed were under the direction of a senior statistician of 
the Statistical Services Unit, The University of Sheffield. Analysis was undertaken to 
investigate the mean clinical mouth score and individual site scores at each time 
point to confirm that treatment was successful at most sites for the majority of 
patients. Subsequent analysis looked at the ability of the biomarker values to predict 
clinical outcome (PPD) at 6 months. Only data applying to subjects who completed 
the study were analysed.  
 
7KH³FRQWLQXRXV´GDWDZHUH WHVWHG IRUQRUPal distribution and thereafter subjected 
to appropriate parametric/non-parametric testing (Shapiro-Wilk test). The Kruskal 
Wallis test was used to find the statistically significant differences in biomarker 
values in the three selected sites and at each time point. Correlations between 
clinical measures and biomarker values were evaluated using 6SHDUPDQ¶V
correlation. An improvement RIPPin PPD was used to dichotomise the outcome 
variable at 6 months.  
 
Receiver operating characteristic curves (ROC) were produced for each biomarker 
and the areas under the curves (AUCs) were used to determine threshold points 
that produced the highest diagnostic sensitivity and specificity.  
 
7RGHWHUPLQHZKHWKHUWKHµELRPDUNHUSURILOH¶LVDXVHIXOSURJQRVWLFWRol for treatment 
outcome, logistic regression analysis was performed with baseline continuous 
values of biomarker levels (as predictors) versus the binary outcome measure 6 
months after treatment as dependent variable. Regression analysis with backward 
stepwise technique was used to exclude redundant biomarkers12. All variables 
included in the final multivariate model were determined to be independent through 
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the assessment of their co-linearity. Odds ratio (OR) estimates and their confidence 
intervals (CI) ZHUH FDOFXODWHG DQG VWDWLVWLFDO VLJQLILFDQFH ZDV GHILQHG DV 3
Statistical power was calculated on the basis that 10 patients should be recruited for 
each of the 10 variables. These variables were the 2 types of sites investigated (DB 
and NB), 3 enzymes, 3 bacteria, 1 for the subject variable and 1 for the change from 
baseline to 6 months. 
 
For validation against independent data, the baseline continuous values of 
biomarkers from the pilot study12 were dichotomised using the threshold points from 
this study. Similarly, the current study was re-analysed using the threshold values 
derived from the pilot study12. Logistic regression was used with binary baseline 
enzyme values using these dichotomised prognostic cut-off points as predictors 
against binary treatment outcome data. All calculations were performed using a 
statistical software package ¤. 
 
Results  
Patients 
101 patients were invited to join the study, 2 patients were excluded according to 
the inclusion/exclusion criteria, 2 failed to attend further appointments and 8 
declined to participate. The 89 remaining patients (44 males and 45 females) had a 
mean age of 49.7±8.9 years (range 30 - 70 years) (30% 30-39, 30% 40-49, 20% 50-
59 and 20% 60 or above), 83 completed the 3-month review and 77 completed the 
full study, of which 8 were smokers. No adverse events were reported as a 
consequence of the study.  
 
Clinical data 
                                                     
§
 SPSS version 20; SPSS Inc., Chicago IL, USA 
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The extent of disease ranged from moderate to severe chronic periodontitis as 
defined by the periodontal disease classification system of 199919.  
 
Full mouth data 
Following initial treatment, plaque (PI) and bleeding (BOP) reductions were 
statistically significant and retreatment at 3 months resulted in further reductions. At 
baseline, approximately two thirds of sites had PPD  mm while the remainder 
were almost equally distributed between PPD of 4-5mm and PPAt 3 months, 
the mean percentage of sites with PPD  PP LQFUHDVHG while the mean 
SHUFHQWDJH RI VLWHV ZLWK 33'  PP KDG GHFreased (p<0.001). At 6 months, 
additional significant improvements were seen, with the mean percentage of healthy 
sites increasing to 82±11  DQG WKH PHDQ SHUFHQWDJH RI VLWHV ZLWK 33'  PP
decreasing to 3% (P<0.0001).   
 
Diseased sites sampled 
Of the sites that were sampled the mean PPDs at baseline for NB sites (6.7±1.1 
mm) and DB sites (6.8±1.2 mm) were not significantly different from each other. At 3 
months after initial treatment, the mean PPDs for both types of sites showed 
statistically significant decreases (ANOVA) to 5.3±1.6 mm (p= 0.0001) and 5.3±1.5 
mm (p= 0.0001) respectively and further reductions to 4.4±1.6 mm (p= 0.0001) and 
4.5±1.7 mm (p= 0.0001), respectively were seen following the second treatment 
phase.  
 
The response to treatment of each of the individual DB and NB sites that were 
sampled are shown in Figures 1 and Supplementary Figure 1 respectively. At 6 
months, 105 sites showed improvement GHILQHGDVPP LPSURYHPHQW LQ33', 
however, 48 sites did not respond adequately.  These included 6 NB sites (8%) and 
13 DB sites (17%) that only partially improved (< 2mm), 12 NB sites (16%) and 8 
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DB sites (10%) that remained unchanged and 5 NB sites (7%) and 4 DB sites (5%) 
that deteriorated.  Responses were similar amongst the subjects who smoked, with 
63% of diseased sites (NB and DB) improving E\PPLQ33'RYHUWKHSHULRG 
 
 
Biomarker levels  
All of the biomarkers tested revealed significant differences in average levels 
between diseased and healthy sites, but bleeding and non-bleeding diseased sites 
at baseline did not differ (Supplementary Table 1). Sites that failed to respond to 
treatment adequately after 6 months (i.e. < 2mm reduction in PPD) generally had 
higher levels of all biomarkers at baseline (Table 1). Over the treatment period, 
comparing baseline measures with those at 6 months, all biomarkers showed a 
statistically significant decrease at diseased sites (Figure 2 and detailed in 
Supplementary Table 2) and the reductions in biomarkers correlated with reduction 
in PPD and outcome of treatment with the exception of levels of F. nucleatum 
(Supplementary Table 2).   
 
Threshold values 
ROC curves, were used to evaluate the ability of biomarkers in GCF and plaque to 
identify whether the site is diseased or healthy. Threshold points with the highest 
sensitivity and specificity were selected for each of the biomarkers at baseline 
(Table 2 and Supplementary Figure 2). Furthermore, the values of MMP8, elastase, 
sialidase P. gingivalis and T. forsythia showed high sensitivity (77 ± 86%) and 
specificity (79 ± 86%) and areas under the curves (0.79 ± 0.92) for diagnosis of 
disease. 
 
Predictive value  
To determine whether the µELRPDUNHU profile¶ is a useful prognostic tool for treatment 
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outcome, logistic regression analysis was performed with baseline biomarker levels 
as independent variables versus the outcome measure of 2mm improvement of 
PPD at the 6 month time point as dependent variable. The data are summarised in 
Tables 3 and 4. For all diseased sites, the three enzyme levels together (MMP8, 
elastase, sialidase) ZHUH DEOH WR SUHGLFW WUHDWPHQW RXWFRPH ZLWK  FHUWDLQW\. 
%DFWHULDO OHYHOVDORQHZHUHDEOH WRSUHGLFW WUHDWPHQWRXWFRPHZLWKFHUWDLQW\
but, when combined with the enzyme biomarkers there was an increase in 
SUHGLFWLRQYDOXHWR7DEOH3). The odds ratio and confidence interval of these 
biomarkers are shown in Table 4. Backward stepwise logistic regression was used 
to exclude the variables that could not add any significant predictive value to the 
combination and it was found that F. nucleatum was a redundant variable (p>0.05) 
while the others were not. Furthermore, each individual biomarker alone was not 
able to predict treatment outcome at a level greater than the null hypothesis (61% in 
NB and 62.5% in DB sites; Table 3). 
Validation of WKHSUHGLFWLYHYDOXHRIWKHµbiomarker SURILOH¶ 
The threshold levels of the GCF enzymes arrived at in this study were used to test 
their sensitivity and specificity for diagnosis and for prognostic value against an 
independent data set. The data used were those reported in the earlier pilot study12 
comprising 22 independent patients. Again ROC curves were used to identify 
specificity and sensitivity and logistic regression to determine predictive value but 
using only GCF enzymes. The diagnostic value of those thresholds was as high for 
the independent validating patient cohort as it was for the patients in this study 
(Supplementary Table 3). Also, the prognostic value of the enzyme threshold levels 
to predict the treatment outcome PP33'LPSURYHPHQW was as high (84%) for 
the independent validation patient cohort as it was for the patients in this study 
(>80%) (Supplementary Table 4).  
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Discussion 
The key finding of the study presented here is that combined high levels of three 
GCF enzymes and two bacteria provide a good prediction for the outcome of non-
surgical treatment on a site specific basis. . While it is acknowledged that there are 
several limitations to the use of biomarkers for diagnosing/predicting disease 
outcome (e.g. appropriate marker selection, validation and robustness of analysis), 
and these can dramatically affect their predictive value, such limitations can be 
reduced by using combinations of different biomarkers, each of which alone may 
not be usefully predictive. The rationale for the study, therefore, was based on the 
premise that periodontal disease has a multifactorial aetiology and so combinations 
of several host and bacterial biomarkers are more likely to provide useful diagnostic 
and prognostic information than single biomarkers. Indeed no individual biomarker 
has yet been demonstrated to be sufficiently reliable for clinical use 5,6,7,11.  
 
We did not seek to discover new, untried biomarkers but we utilised ones for which 
there has been clear evidence of association with disease. MMP-8 and elastase 
were selected because they are secreted by neutrophils20. Sialidase was selected 
as it is mainly of bacterial origin and produced by the red-complex pathogens 
Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola with 
evidence that it plays a role in pathogenesis21,22.  Furthermore our pilot study 
identified raised sialidase in GCF of diseased sites12, while others detected 
Tannerella sialidase gene (nanH) at high levels in periodontal plaque RNA23. These 
enzymes have been investigated individually by others in relation to periodontal 
disease24-27 but not in combination and here we have also included assessment of 
the level of selected key bacterial species considered to be aetiologically important 
contributors to chronic periodontitis and its progression as potential biomarkers28--30.   
While ideally one would conduct a qPCR study of a larger number of bacterial spp., 
for practical reasons (particularly availability of control DNA material) and given their 
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prominence and close-association, we focussed on P. gingivalis and T. forsythia as 
UHSUHVHQWDWLYH µUHG-FRPSOH[¶SHULRGRQWDOSDWKRJHQV14.   However, we acknowledge 
that ideally we would have included T. denticola or Filifactor alocis.  We did, 
however, include F. nucleatum as a positive internal control since that would be 
expected to be present in all samples as it acts as a µEULGJLQJ¶species in the oral 
biofilm31,32. Moreover, plaque samples were collected using curettes, which others 
have shown to yield higher levels of bacterial DNA than paper points32. 
 
Our findings strongly suggest that baseline concentrations of active MMP8, elastase 
and sialidase can not only be used to diagnose a diseased site but when combined 
also predict its likely response to treatment. The enzyme levels correlated with initial 
PPD, and with the exception of sialidase is in agreement with other information in 
the literature34-38. Our pilot study was the first to report the predictive value of 
sialidase in combination12 and those data have been upheld in this larger cohort 
study. In both this and our pilot study we used the ROC curve to determine whether 
a given enzyme level could act as a threshold point to differentiate health from 
disease. The resultant diagnostic sensitivity and specificity for each enzyme was 
>78%, which for MMP-8 and elastase is in keeping with some earlier studies6,7,39-41.  
 
While these findings for diagnosis are useful, we feel that the primary value of a 
µELRPDUNHU SURILOH¶ ZRXOG EH if it is able to predict the outcome of non-surgical 
periodontal treatment or disease progression. Consequently in the current study we 
looked beyond the diagnostic value of the biomarkers and used backward stepwise 
logistic regression WR HYDOXDWH HDFK ELRPDUNHU¶V FRQWULEXWLRQ WR WKH µSURILOH¶V¶
predictive value. The latter were judged against the primary treatment outcome 
measure (i.e. an improvement of 2mm in PPD11,42)  
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These findings expand and improve upon recent reports that a raised MMP8 level is 
a good predictor of treatment outcome7,11,41, and that elastase might be useful for 
predicting disease progression43,44.  In addition, while Beighton25 showed that 
sialidase could differentiate between gingivitis and periodontitis, to the best of our 
knowledge we are the first to report the correlation of initial GCF sialidase levels 
with treatment outcome.  
 
The mere presence and absence of key bacterial species is not sufficient to 
distinguish healthy sites from diseased sites and it is generally accepted that an 
increase in the level of certain species is important45-48. Indeed we found that the 
proportions of P. gingivalis and T. forsythia above the critical threshold points of 
0.23% and 0.35% respectively, were associated with disease (sensitivities and 
specificities > 77%).  In terms of response to treatment, while there is much data 
indicating that the levels of T. forsythia and P. gingivalis at diseased sites reduce 
during treatment, there is a shortage of data on the usefulness of these bacteria as 
prognostic tools and the current study contributes to filling this research gap. Using 
logistic regression analysis we found that high levels of P. gingivalis and T. forsythia 
at were associated with sites that failed to respond to treatment compared with sites 
that did respond. This is in agreement with some findings in a study by Kinney7. 
Consequently by adding the levels of WKHVH VSHFLHV LQWR WKH µSURILOH¶ of the three 
GCF enzymes, the predictive power for treatment outcome was raised from ~80% 
to >92%. It should be stressed, therefore, that our findings strongly indicate that 
high levels of the three enzymes, supplemented by high levels of P. gingivalis T. 
forsythia, at initial assessment predicts a poor outcome for those sites when 
conventional treatment is used. Thus, knowledge of the total combined profile of 
these biomarkers at patient assessment provides information that is useful in 
directing treatment. 
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To validate the predictive value of this µELRPDUNHU SURILOH ZH WHVWHG WKH WKUHVKROG
values determined here against the clinical data of an independent cohort of 22 
patients. These patients have been described previously by Gul12 but only GCF 
enzyme data were available for these subjects so we could only validate against the 
three enzyme biomarkers. The enzyme threshold points determined here 
maintained a high level of sensitivity and specificity for predicting the outcome of 
treatment proving that they are reliable in different sample cohorts. Further testing is 
required, however, particularly in cohorts of challenging patients, for example those 
with diabetes mellitus. 
We also acknowledge some limitations to the study, in addition to those mentioned 
earlier, but feel that despite these the work and the study not only stands alone but 
also presents novel aspects and avenues for study and diagnosis of periodontal 
disease. Firstly, our power calculation indicated an ideal study population of 100 
would be required, but while we encountered some patient drop-out (12/101) we 
calculated early on in the work that both levels of Fusobacterium and a lack of 
differences in response between DB and NB sites essentially made them redundant 
variables and so our study was adequately powered.   In addition we found during 
the study that bleeding on probing (BoP) was too variable a measure given its 
subjective nature and so employed a more rigorous primary outcome measure of > 
2mm improvement in PPD which is accepted as being outside inter-examiner 
variability11. . 
Examining all sites in a patient would be the ultimate aim given the site-specific 
nature of chronic periodontitis, but this was not feasible in this study due to patient 
numbers and time required. However, finding that the data from this study patient 
cohort matches that from an independent study group provides strong validation 
and confidence in our findings. Finally, it would be of great interest to examine the 
relationship between the chosen biomarkers and disease onset, transition from 
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gingivitis to periodontitis, or whether a site is undergoing active destruction, all 
avenues that further work should explore to improve prognosis and guide treatment. 
Conclusion 
This study has shown that knowledge of the levels of three GCF enzymes plus two 
bacterial species at a site comprises a unique µELRPDUNHUSURILOH¶or fingerprint that is 
useful for predicting the outcome of periodontal treatment. This is important since 
one of the commonest decisions that periodontists must make is whether to provide 
rigorous treatment, such as surgery plus systemic antibiotic therapy, or whether to 
limit treatment to more conservative measures (scaling and root surface 
debridement). While clearly taking this data forward to producing a chairside test is 
challenging, our data indicate that this is an avenue worth pursuing and that this 
µELRPDUNHU SURILOLQJ¶ PLJKW DLG LQ WUHDWPHQW UHJLPHQ GHFLVLRQ PDNLQJ DQG WKXV
improve patient outcomes for this chronic hard-to-treat but large global burden 
disease.   
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Figure Legends 
Figure 1 
Chart showing changes in PPD of all deep bleeding (DB) sites from baseline to 6 
Baseline PPD;    Site did not change;  months post treatment.       
 Site improved by > 2mm;     Site improved by < 2mm;   Site deteriorated    
 
Figure 2 
Chart showing changes in the six biomarkers at all healthy, deep non-bleeding (NB) 
and deep bleeding (DB) sites from baseline to 6 months post treatment. 
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Tables 
 
Table 1. Analysis of baseline median biomarker levels (ng/µl enzymes; % total bacteria) 
in respondent sites (n= 105) versus non-respondent sites (n= 48). 
 
Disease sampled 
site 
Biomarker 
(Baseline) 
Respondent  
(median) 
 
Non-Respondent 
(median) 
 
p value* 
 
NB sites 
MMP8  122 231 0.003 
Elastase  68 307 0.001 
Sialidase  10 26 0.001 
Pg% 0.58 2.3 0.007 
Tf % 0.1 5.64 0.0001 
Fn% 4.03 4.19 0.6 
 
 
DB sites 
MMP8  138 352 0.001 
Elastase  53 447 0.001 
Sialidase 4.2 35 0.001 
Pg% 0.88 3.58 0.0001 
Tf % 0.3 7.13 0.0001 
Fn% 4.82 4.14 0.53!
* Kruskal Wallis 
 
Table 2. Diagnostic properties of specific thresholds of the three GCF enzymes and 
key bacteria in plaque 
 
Variable Threshold 
(ng/ȝO 
Sensitivity%/ 
Specificity% 
Area under 
the curve 
95% CI for OR p value 
LCL UCL 
MMP8 94 86/83 0.92 0.89 0.95 0.0001 
Elastase 33 78/80 0.87 0.83 0.91 0.0001 
Sialidase 2.3 79/79 0.79 0.72 0.83 0.0001 
Pg% 0.23 77/86 0.81 0.71 0.86 0.0001 
Tf% 0.35 78/84 0.8 0.77 0.89 0.0001 
Fn% 2.94 65/65 0.62 0.52 0.71 0.017 
LCL lower confidence limit; UCL upper confidence limit 
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Table 3. Logistic regression analysis with 2mm PPD improvement (at 6 months) as the 
dependent variable. 
 
 Method NB sites DB sites 
Predictive Predictive 
GCF biomarkers 
All variables 
81.3%(MMP8, 
elastase, sialidase) 
80.3% (MMP8, 
elastase, 
sialidase,) 
Bacterial biomarkers All 76% 
(Pg%, Tf%, Fn%) 
76% 
(Pg%, Tf%, Fn%) 
Stepwise 
(backward 
conditional) 
76% 
(Pg%, Tf%) 
74% 
(Pg%, Tf%) 
Combined GCF 
enzymes and bacterial 
biomarkers 
(MMP8, elastase, 
sialidase, Pg%, 
Tf%) 
92% 
 
93.3% 
 
Each single biomarker  61% 62.5%  
Pg: P. gingivalis, Tf: T. forsythia, Fn: F. nucleatum 
 
 
Table 4 Summary of logistic regression for each individual explanatory variable for response of 
diseased sites by 6 months post treatment. 
 
Disease 
sampled site 
Predictor 
variable 
Effects 
ȕ 
Odds Ratio 
(OR) 
95% CI for OR p value * 
LCL UCL 
 
 
NB 
MMP8 -0.005 0.995 0.99 1.3 0.006 
Elastase -0.006 0.994 0.99 1.2 0.002 
Sialidase -0.002 0.998 0.99 1.2 0.03 
Pg% -1.2 0.28 0.1 0.7 0.001 
Tf% -0.6 0.53 0.3 0.7 0.001 
Fn% -0.05 0.94 0.5 1.6 0.8 
 
 
DB 
MMP8 -0.005 0.995 0.99 1.3 0.007 
Elastase -0.005 0.995 0.99 1.3 0.001 
Sialidase -0.006 0.994 0.99 1.3 0.001 
Pg% -0.32 0.68 0.4 1.1 0.01 
Tf% -0.5 0.55 0.3 0.7 0.001 
Fn% 0.12 1.1 0.8 1.5 0.4 
Pg: P. gingivalis, Tf: T. forsythia, Fn: F. nucleatum. * Mann Whitney test 
Figure 1
Figure 2
